# Alexion Pharmaceuticals (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/alexion-pharmaceuticals-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 33.7 |
| Citations | 169,643 |
| City | Boston |
| Country | US |
| Description | Alexion Pharmaceuticals (United States) is a research organisation in Boston, US. OpenAlex records 1,356 works and 169,643 citations for it. 466 researchers list it as their most recent affiliation. |
| Homepage | http://alexion.com/ |
| OpenAlex ID | https://openalex.org/I4210125492 |
| Region | Massachusetts |
| Researchers | 466 |
| ROR ID | https://ror.org/031ywxc85 |
| Type | company |
| Works | 1,356 |

## University papers

Showing 12 of 28.

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma](https://scholariq.org/papers/dupilumab-efficacy-and-safety-in-moderate-to-severe-uncontrolled-asthma/)
- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-glucocorticoid-dependent-severe-asthma/)
- [Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis](https://scholariq.org/papers/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adolescents-with-uncontrolled-moderate-to/)
- [Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t](https://scholariq.org/papers/dupilumab-with-concomitant-topical-corticosteroid-treatment-in-adults-with/)
- [Conjunctivitis in dupilumab clinical trials](https://scholariq.org/papers/conjunctivitis-in-dupilumab-clinical-trials/)
- [Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis](https://scholariq.org/papers/peak-pruritus-numerical-rating-scale-psychometric-validation-and-responder/)
- [Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults](https://scholariq.org/papers/patient-burden-of-moderate-to-severe-atopic-dermatitis-ad-insights-from-a-phase/)

## University researchers

- [Simu K. Thomas](https://scholariq.org/researchers/simu-k-thomas/)

## University top topics

Showing 8 of 25.

- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Blood groups and transfusion](https://scholariq.org/topics/blood-groups-and-transfusion/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Coagulation, Bradykinin, Polyphosphates, and Angioedema](https://scholariq.org/topics/coagulation-bradykinin-polyphosphates-and-angioedema/)
- [Myasthenia Gravis and Thymoma](https://scholariq.org/topics/myasthenia-gravis-and-thymoma/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Hemoglobinopathies and Related Disorders](https://scholariq.org/topics/hemoglobinopathies-and-related-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.